Difference between revisions of "Mayo score"
Jump to navigation
Jump to search
(UC -> to IBD) |
|||
| Line 1: | Line 1: | ||
'''Mayo score''' is used by some endoscopists to grade [[ | '''Mayo score''' is used by some endoscopists to grade [[inflammatory bowel disease]] activity.<ref name=pmid26071941>{{Cite journal | last1 = Peyrin-Biroulet | first1 = L. | last2 = Panés | first2 = J. | last3 = Sandborn | first3 = WJ. | last4 = Vermeire | first4 = S. | last5 = Danese | first5 = S. | last6 = Feagan | first6 = BG. | last7 = Colombel | first7 = JF. | last8 = Hanauer | first8 = SB. | last9 = Rycroft | first9 = B. | title = Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. | journal = Clin Gastroenterol Hepatol | volume = 14 | issue = 3 | pages = 348-354.e17 | month = Mar | year = 2016 | doi = 10.1016/j.cgh.2015.06.001 | PMID = 26071941 }}</ref> | ||
==Background== | ==Background== | ||
Latest revision as of 14:53, 5 April 2023
Mayo score is used by some endoscopists to grade inflammatory bowel disease activity.[1]
Background
The system was described in a 1987 article written by Mayo Clinic staff.[2]
Details
The system consists for four separate parts:[2]
- Stool frequency (0-3).
- Rectal bleeding (0-3).
- Endoscopic findings (0-3).
- Physician global assessment (0-3).
Notes:
- "0" is normal, "1" is mild, "2" is moderate, and "3" is severe.
See also
References
- ↑ Peyrin-Biroulet, L.; Panés, J.; Sandborn, WJ.; Vermeire, S.; Danese, S.; Feagan, BG.; Colombel, JF.; Hanauer, SB. et al. (Mar 2016). "Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.". Clin Gastroenterol Hepatol 14 (3): 348-354.e17. doi:10.1016/j.cgh.2015.06.001. PMID 26071941.
- ↑ 2.0 2.1 Schroeder, KW.; Tremaine, WJ.; Ilstrup, DM. (Dec 1987). "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.". N Engl J Med 317 (26): 1625-9. doi:10.1056/NEJM198712243172603. PMID 3317057.